1037 related articles for article (PubMed ID: 24954536)
21. KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
[TBL] [Abstract][Full Text] [Related]
22. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance.
Zhou D; Zhang Y; Wu H; Barry E; Yin Y; Lawrence E; Dawson D; Willis JE; Markowitz SD; Camargo FD; Avruch J
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1312-20. PubMed ID: 22042863
[TBL] [Abstract][Full Text] [Related]
23. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer.
Zhong X; Zheng L; Shen J; Zhang D; Xiong M; Zhang Y; He X; Tanyi JL; Yang F; Montone KT; Chen X; Xu C; Xiang AP; Huang Q; Xu X; Zhang L
Mol Cell Biol; 2016 Nov; 36(21):2742-2754. PubMed ID: 27550813
[TBL] [Abstract][Full Text] [Related]
24. Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21.
Escandell JM; Kaler P; Recio MC; Sasazuki T; Shirasawa S; Augenlicht L; Ríos JL; Klampfer L
Biochem Pharmacol; 2008 Jul; 76(2):198-207. PubMed ID: 18561895
[TBL] [Abstract][Full Text] [Related]
25. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
[TBL] [Abstract][Full Text] [Related]
26. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
[TBL] [Abstract][Full Text] [Related]
27. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
28. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
29. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
30. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis.
Rosenbluh J; Nijhawan D; Cox AG; Li X; Neal JT; Schafer EJ; Zack TI; Wang X; Tsherniak A; Schinzel AC; Shao DD; Schumacher SE; Weir BA; Vazquez F; Cowley GS; Root DE; Mesirov JP; Beroukhim R; Kuo CJ; Goessling W; Hahn WC
Cell; 2012 Dec; 151(7):1457-73. PubMed ID: 23245941
[TBL] [Abstract][Full Text] [Related]
31. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
[TBL] [Abstract][Full Text] [Related]
32. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
33. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
[TBL] [Abstract][Full Text] [Related]
34. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
35. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
37. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
[TBL] [Abstract][Full Text] [Related]
38. Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion.
Zhang H; von Gise A; Liu Q; Hu T; Tian X; He L; Pu W; Huang X; He L; Cai CL; Camargo FD; Pu WT; Zhou B
J Biol Chem; 2014 Jul; 289(27):18681-92. PubMed ID: 24831012
[TBL] [Abstract][Full Text] [Related]
39. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
[TBL] [Abstract][Full Text] [Related]
40. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway.
Li M; Lu J; Zhang F; Li H; Zhang B; Wu X; Tan Z; Zhang L; Gao G; Mu J; Shu Y; Bao R; Ding Q; Wu W; Dong P; Gu J; Liu Y
Cancer Lett; 2014 Dec; 355(2):201-9. PubMed ID: 25218593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
